||5R03CA089798-02 Interpret this number
||Wake Forest University Health Sciences
||Cadmium & Pancreatic Cancer: a Pilot Case-Control Study
DESCRIPTION (provided by applicant):
Little is known about the etiology of pancreatic cancer, which causes more
than 29,000 deaths per year in the U.S. The P.I. recently proposed that
cadmium is a cause of pancreatic cancer (Cancer Epidemiology, Biomarkers
&Prevention, 9:139-145, 2000). Cadmium is a non-essential metal that
accumulates in the human pancreas. Cadmium is known to cause pancreatic cancer
in animals and is a plausible cause of pancreatic cancer in humans.
We will conduct a pilot, hospital-based case-control study to determine
whether exposure to cadmium, as measured by questionnaire data on dietary,
occupational and recreational exposure to cadmium, and by measurements of
cadmium in urine, predicts risk for pancreatic cancer. We hypothesize that,
controlling for age and smoking history, reported exposure to cadmium and
cadmium levels in urine will be higher from persons with pancreatic cancer
than from persons without pancreatic cancer.
Our Specific Aims are to:
1. Recruit 50 patients with incident cancer of the exocrine pancreas (cases)
seen at Wake Forest University Baptist Medical Center (WFUBMC).
2. Recruit two sets of control patients:
a. 50 patients matched on race, gender, smoking history, and age (4- 5 years)
without cancer seen inthe Department of Gastroenterology (G.I.) at WFUBMC (the
clinic referral population)
b. 50 patients matched on race, gender, smoking history, and age (4-5 years)
without cancer seen at General Internal Medicine clinics at WFUBMC (the
hospital referral population).
3. Obtain informed consent, urine samples, and questionnaire data for cases
4. Analyze these data to determine risk of pancreatic cancer from: cadmium in
urine, corrected for creatinine levels (a biomarker of exposure to cadmium),
reported exposure to cadmium, and retinol binding protein in urine (a measure
of biological effect of exposure to cadmium).
5. Secondarily, analyze urine specimens for zinc and copper and compare tile
patient groups with respect to the zinc:cadmium ratio, and to the
concentrations of copper.
Cadmium and renal cancer.
, Schwartz G.G.
Toxicology and applied pharmacology, 2005-09-01; 207(2), p. 179-86.
Urinary cadmium, impaired fasting glucose, and diabetes in the NHANES III.
, Il'yasova D.
, Ivanova A.
Diabetes care, 2003 Feb; 26(2), p. 468-70.